Napolitano Maddalena, Ferrillo Maria, Patruno Cataldo, Scalvenzi Massimiliano, D'Andrea Mirella, Fabbrocini Gabriella
Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Dermatol Ther (Heidelb). 2021 Apr;11(2):355-361. doi: 10.1007/s13555-021-00505-z. Epub 2021 Mar 13.
We have read with great interest the article by Kreeshan et al., which reported data on effectiveness and laboratory safety of dupilumab. We performed a retrospective study including 165 adult patients affected by moderate-to-severe atopic dermatitis (AD) and treated with dupilumab for at least 52 weeks. A significant improvement in eczema area severity index (EASI) score after 16 and 52 weeks of treatment with dupilumab was observed. The mean EASI score at baseline was 28.84 ± 6.4 and significantly reduced to 10.05 ± 8.00 at 16 weeks (p < 0.001), and to 3.04 ± 4.73 at 52 weeks (p < 0.001), with a mean percentage reduction of 65.15% and 89.45%, respectively. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores (P-NRS, S-NRS and DLQI). Furthermore, no patient discontinued the drug because of inefficacy. Fifty-seven out of 165 (34.54%) patients reported at least one adverse event (AE) during the 52-week treatment. Our study confirms that dupilumab can represent a long-term treatment for moderate-to-severe adult AD, beyond 16 weeks. In our experience, dupilumab demonstrated a favourable safety profile at 52 weeks and only a few patients had to discontinue the treatment because of AEs.
我们饶有兴趣地阅读了Kreeshan等人的文章，该文章报道了度普利尤单抗的有效性和实验室安全性数据。我们进行了一项回顾性研究，纳入了165例中重度特应性皮炎（AD）成年患者，这些患者接受度普利尤单抗治疗至少52周。观察到度普利尤单抗治疗16周和52周后，湿疹面积和严重程度指数（EASI）评分有显著改善。基线时EASI评分的平均值为28.84±6.4，在16周时显著降至10.05±8.00（p<0.001），在52周时降至3.04±4.73（p<0.001），平均降低百分比分别为65.15%和89.45%。度普利尤单抗的疗效通过所有评分（P-NRS、S-NRS和DLQI）的显著降低得到证实。此外，没有患者因无效而停药。165例患者中有57例（34.54%）在52周治疗期间报告了至少1次不良事件（AE）。我们的研究证实，度普利尤单抗可作为中重度成年AD超过16周的长期治疗药物。根据我们的经验，度普利尤单抗在52周时显示出良好的安全性，只有少数患者因AE不得不停药。
